Sodium–glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk
Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, Matteo Barbato, Raffaele Arianna, Pietro Forte, Jacopo Santagata, Carlo Maurea, Maria Laura Canale, Andrea Paccone, Alessandro Inno, Cristiana D’Ambrosio, Stefano Oliva, Christian Cadeddu Dessalvi, Tiziana Di Matola, Domenico Gabrielli, Nicola Maurea · 2026
Read Sodium–glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic risk by Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, Matteo Barbato, Raffaele Arianna, Pietro Forte, Jacopo Santagata, Carlo Maurea, Maria Laura Canale, Andrea Paccone, Alessandro Inno, Cristiana D’Ambrosio, Stefano Oliva, Christian Cadeddu Dessalvi, Tiziana Di Matola, Domenico Gabrielli, Nicola Maurea (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13548579.txt.
Description
Vincenzo Quagliariello and colleagues review whether a class of diabetes drugs could protect the hearts and metabolism of breast cancer survivors, in a 2026 narrative review. Hormone-driven breast cancer is common, and hormone-blocking treatment saves lives while raising fat around the organs, disturbing lipids, and inflaming blood vessels. Heart disease has become a leading non-cancer killer in this group, prompting interest in sodium-glucose cotransporter 2 inhibitors.
These drugs, first made to lower blood sugar, also guard the heart and kidneys. The review gathers laboratory, animal, and observational evidence that they calm insulin signaling, fat tissue inflammation, liver fat, and vessel dysfunction, and may even counter hormone therapy resistance. Matched patient studies in cancer populations are summarized with caution. The authors frame the drugs as a targeted candidate strategy needing direct trials in survivors on hormone therapy.
Catalog record
| CREATOR | Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, Matteo Barbato, Raffaele Arianna, Pietro Forte, Jacopo Santagata, Carlo Maurea, Maria Laura Canale, Andrea Paccone, Alessandro Inno, Cristiana D’Ambrosio, Stefano Oliva, Christian Cadeddu Dessalvi, Tiziana Di Matola, Domenico Gabrielli, Nicola Maurea |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70108 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |